文献速递慢阻肺

靶向肺去神经术治疗慢阻肺的随机假手术对照试验(AIRFLOW-3)

Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3).
PubMed 文献 · Am J Respir Crit Care Med · 2025-01-01

AIRFLOW-3是一项1:1随机双盲假手术对照试验,纳入388例有症状且频繁急性加重的慢阻肺患者,评估D'Nerva靶向肺去神经术(TLD)联合最佳药物治疗对比假手术联合最佳药物治疗对急性加重的影响。主要终点12个月内首次中重度急性加重时间在两组间无差异(HR 1.268,95%CI 0.988-1.628),但TLD组1年呼吸困难改善(TDI>1分)比例更高(35.4% vs 24.1%,P=0.021)。事后分析提示主要终点未达到可能与气道主导表型患者比例不足有关。

要点

  • TLD未显著延长12个月内首次中重度慢阻肺急性加重时间(HR 1.268,95%CI 0.988-1.628)。
  • TLD组1年TDI改善>1分的比例高于假手术组(35.4% vs 24.1%,P=0.021)。
  • 事后分析提示气道主导表型(肺过度充气无明显肺气肿)患者可能获益。

核心结论

  • AIRFLOW-3未达到主要终点,即TLD联合最佳药物治疗未显著改善12个月内首次中重度慢阻肺急性加重时间。
  • 事后分析识别出可能应答者特征,但需前瞻性多中心随机对照试验确认。

研究设计与样本

  • 1:1随机、双盲、假手术对照试验,在32个中心纳入388例慢阻肺患者。
  • 纳入标准:有症状(CAT评分≥10)、中度至极重度气流受限(FEV1≥25%且≤80%预计值)、GOLD E组(过去12个月至少2次中度或1次重度急性加重)。
  • 主要终点为12个月内首次中重度慢阻肺急性加重时间的组间比较(TLD+最佳药物治疗 vs 假手术+最佳药物治疗)。

主要发现

  • 治疗组与假手术组发生中重度慢阻肺急性加重的概率无差异(HR 1.268,95%CI 0.988-1.628)。
  • 1年时TLD组TDI改善>1分的比例高于假手术组(35.4% vs 24.1%,P=0.021)。
  • 事后分析提示主要终点未达到可能与气道主导表型(肺过度充气无明显肺气肿)患者数量不足有关。

临床怎么用

  • 目前不推荐将TLD常规用于慢阻肺急性加重预防,需等待确证性试验结果。
  • 对气道主导表型(肺过度充气无明显肺气肿)患者,TLD可能改善呼吸困难,但属事后分析需谨慎。

局限性

  • 主要终点未达到,事后分析识别应答者特征仅为假设生成。
  • 气道主导表型患者比例不足可能影响主要终点结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: AIRFLOW-3 was a 1:1 randomized, double-blind, sham-controlled trial of the D'Nerva targeted lung denervation (TLD) system in patients with chronic obstructive pulmonary disease (COPD). Objective: To evaluate the impact of TLD on COPD exacerbations compared with optimal medical treatment. Methods: AIRFLOW-3 patients were symptomatic (COPD Assessment Test score ⩾10) with moderate to very severe airflow obstruction (FEV1 ≥25% but ⩽80% predicted) and Global Initiative for Chronic Obstructive Lung Disease E status (at least two moderate or one severe exacerbation during the previous 12 mo). The primary endpoint was a comparison of time to the first moderate or severe COPD exacerbation through 12 months between the treatment (TLD plus optimal medical treatment) and sham control groups (sham procedure plus optimal medical treatment). Secondary endpoints included the rate of severe COPD exacerbations, change in quality of life (St. George's Respiratory Questionnaire for COPD and Short Form-36 questionnaire), change in lung function (FVC, FEV1, residual volume), and change in COPD Assessment Test score. Measurements and Main Results: 388 patients were randomized at a 1:1 ratio at 32 sites. There was no difference between treatment and the sham procedure in terms of the probability of participants having a moderate or severe COPD exacerbation (hazard ratio, 1.268; 95% confidence interval, 0.988-1.628). At 1 year, the TLD group had less dyspnea (>1-point improvement in Transitional Dyspnea Index, 35.4 vs. 24.1%; P = 0.021) compared with the sham group. Post hoc analyses suggests that failure to reach the primary endpoint was driven by an insufficient number of patients exhibiting an airway-predominant phenotype (lung hyperinflation without significant emphysema). Conclusions: AIRFLOW-3 failed to meet its primary endpoint. However, post hoc analyses identified a responder profile; a prospective multicenter randomized controlled trial is being designed to confirm these findings. Clinical trial registered with www.clinicaltrials.gov (NCT03639051).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Shah, Slebos, Sue, et al. Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3). Am J Respir Crit Care Med. 2025. PMID: 40920914. doi:10.1164/rccm.202502-0404OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。